Clinical Trials (PDQ®) - National Cancer Institute

Page Options

Clinical Trial Questions?

Get Help:

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

Trial of 13-Cis Retinoic Acid, Alpha Interferon, Taxotere, and Estramustine (R.I.T.E.) for the Treatment of Hormone Refractory Prostate Cancer

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase II Treatment Active 18 and over Other CDR0000540176
3850, CINJ#080107, NCT00176527

Trial Description

Summary

This study will be for patients with prostate cancer that has not responded to hormonal therapy.

Further Study Information

The purpose will be to determine how well prostate cancer responds to treatment with the predetermined dose of docetaxel as part of the new combination of four drugs.

Eligibility Criteria

Inclusion Criteria:

Patients with histologically proven metastatic prostate cancer and progression after initial hormonal therapy will be eligible.

Full recovery from the effects of any prior surgery or radiation therapy.

Patients cannot have had prior chemotherapy, retinoids, or interferon therapy.

Exclusion Criteria:

Patients with active infections or known infection with HIV.

The discontinuation of flutamide or bicalutamide within 4 or 6 weeks respectively.

Trial Contact Information

Trial Lead Organizations/Sponsors

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School

Department of Defense

Robert S. DiPaola, MD

Principal Investigator

Cho Chan, RN		Ph: 732-235-8092
		Email: chanc2@umdnj.edu

Trial Sites

U.S.A.

New Jersey

New Brunswick

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School

Cho Chan, RN Ph: 732-235-8092

Email: chanc2@umdnj.edu

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00176527
Information obtained from ClinicalTrials.gov on April 26, 2007

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.